NASDAQ : DFTX
Definium Therapeutics, Inc. — Key statistics
United States
Last price 37.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.10B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.36B |
| Enterprise Value | 3.32B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 134.37M |
| Shares Outstanding | 134.37M |
| Shares Change (YoY) | +22.22% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 81.96% |
| Float | 125.52M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.75 |
| P/TBV Ratio | 4.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.95 |
| Quick Ratio | 6.89 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.33 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -64.09% |
| Return on Assets (ROA) | -20.64% |
| Return on Invested Capital (ROIC) | -24.06% |
| Return on Capital Employed (ROCE) | -23.81% |
| Weighted Average Cost of Capital (WACC) | 16.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.34M |
| Employee Count | 106 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +128.66% |
| 50-Day Moving Average | 37.52 |
| 200-Day Moving Average | 29.69 |
| Relative Strength Index (RSI) | 37.37 |
| Average Volume (20 Days) | 1,953,722 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.04M |
| Short Previous Month | 11.34M |
| Short % of Shares Out | 7.48% |
| Short % of Float | 8.00% |
| Short Ratio (days to cover) | 4.32 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -227.54M |
| Pretax Income | -353.79M |
| Net Income | -353.79M |
| EBITDA | n/a |
| EBIT | -227.54M |
| Earnings Per Share (EPS) | -$3.48 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.08B |
| Total Debt | 36.47M |
| Net Cash | 1.05B |
| Net Cash Per Share | $7.80 |
| Equity (Book Value) | 918.68M |
| Book Value Per Share | 6.84 |
| Working Capital | 934.90M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -167.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -167.95M |
| FCF Per Share | -$1.25 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -22.22% |
| Shareholder Yield | -22.22% |
| Earnings Yield | -10.72% |
| FCF Yield | -3.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $72.56 |
| Price Target Difference | 123.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 29, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |